Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3
暂无分享,去创建一个
Young Tae Kim | E. Nam | G. Yim | H. Kim | Eun Ji Nam | Hee Jung Kim | Ga Won Yim
[1] R. Chen,et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.
[2] W. Grizzle,et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] F. Ognibene,et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. , 1994, Journal of the National Cancer Institute.
[4] Douglas B. Evans,et al. The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .
[5] D. Huntsman,et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours , 2005, Breast Cancer Research.
[6] A. Letai,et al. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. , 2008, Cancer research.
[7] Yi Huang,et al. IκB Kinase Activation Is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines , 2002 .
[8] Y. Song,et al. Akt Involvement in Paclitaxel Chemoresistance of Human Ovarian Cancer Cells , 2007, Annals of the New York Academy of Sciences.
[9] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[10] N. Maggiano,et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Testa,et al. Inhibition of Inhibitor of Nuclear Factor-κB Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models , 2004, Clinical Cancer Research.
[12] Yi Huang,et al. IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. , 2002, Molecular pharmacology.
[13] Robert C. Bast,et al. Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.
[14] Jing Yang,et al. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib , 2010, Journal of Cancer Research and Clinical Oncology.
[15] Kazuhiro Takahashi,et al. Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.
[16] D. Schrump,et al. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. , 2004, The Journal of thoracic and cardiovascular surgery.
[17] M. Karamouzis,et al. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas , 2006, Journal of Cancer Research and Clinical Oncology.
[18] Gong Yang,et al. The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer , 2011, Clinical Cancer Research.
[19] W. Vainchenker,et al. Inhibition of the erythropoietin-induced erythroid differentiation by granulocyte-macrophage colony-stimulating factor in the human UT-7 cell line is not due to a negative regulation of the erythropoietin receptor. , 1996, Blood.
[20] S. Grösch,et al. COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] J. Morrow,et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[22] J. Long,et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. , 2005, World journal of gastroenterology.
[23] R. DuBois,et al. The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.
[24] J. McCubrey,et al. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. , 2012, Cancer letters.
[25] M. Altinoz,et al. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. , 2004, Neoplasma.
[26] NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. , 1995, JAMA.
[27] R. Parker,et al. A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma , 2010, Cancer.